Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC competition head departs

This article was originally published in The Tan Sheet

Executive Summary

David Wales leaves in May after nine months as acting director of the Federal Trade Commission's Bureau of Competition, the agency says in an April 2 statement. Wales joined FTC in April 2006 as deputy director of the bureau and oversaw cases including the settlement of the Whole Foods and Wild Oats Markets merger, and Inverness Medical Innovations' alleged anticompetitive purchase of a pregnancy test technology (1"The Tan Sheet" Dec. 1, 2008, In Brief and 2"The Tan Sheet" Jan. 5, 2009, p. 14)

You may also be interested in...

Inverness Forced To Release Pregnancy Test Technology

Inverness Medical Innovations must clear a path for the introduction of a water-soluble dye technology for consumer pregnancy tests under a settlement with the Federal Trade Commission

Whole Foods rehearing petition denied

The U.S. Court of Appeals for the District of Columbia Circuit rejects the supermarket chain's request for a rehearing en banc concerning its acquisition of Wild Oats Markets, following the court's July ruling in favor of the Federal Trade Commission, according to a Nov. 21 order. FTC claims the merger between Austin, Texas-based Whole Foods and Boulder, Colo.-based Wild Oats limits competition in the "premium, natural and organic supermarket" segment. "We look forward to presenting our evidence as to why this merger is unlawful" at the administrative trial before the commission, scheduled for Feb. 16, says David Wales, FTC's Bureau of Competition acting director. Wales adds the agency wants to maintain competition and reach "a meaningful remedy." FTC indicated interest in settling, though Whole Foods may seek certiorari before the Supreme Court, which has shown pro-merger sentiments (1"The Tan Sheet" Aug. 18, 2008, p. 6)

Mylan Weighs In On Coronavirus Drug Shortage Concerns

Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business. 






Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts